References
1. Pollack, V.A., Savage, D.M., Baker, D.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. Journal of Pharmacology and Experimental Therapeutics 291, 739-748 (1999). 2. Greulich, H., Chen, T.H., Feng, W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2(11), (2005). 3. Yamasaki, F., Zhang, D., Bartholomeusz, C., et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol. Cancer Ther. 6(8), 2168-2177 (2007). 4. Li, Z., Xu, M., Xing, S., et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J. Biol. Chem. 282(6), 3428-3432 (2007). 5. Herbst, R.S., and Bunn, P.A., Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 9(16), 5813-5824 (2003). 6. Gerber, D.E. EGFR inhibition in the treatment of non-small cell lung cancer. Drug Dev. Res. 69(6), 359-372 (2008).USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
